40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations
G. Korukluoglu, M. Kolukirik, F. Bayrakdar, G. G. Ozgumus, A. B. Altas, Y. Cosgun, C. Z. Ketre Kolukirik
Abstract
A one-step reverse transcription and real-time PCR (RT-qPCR) test was developed for rapid screening (40 minutes) of the Spike N501Y and HV69-70del mutations in SARS-CoV-2 positive samples. The test also targets a conserved region of SARS-CoV-2 Orf1ab as an internal control. The samples containing both the N501Y and HV69-70del mutations are concluded as VOC-202012/01 positive. Samples suspected to be positive for B.1.351 or P.1 are the N501Y positive and HV69-70del negative cases. Limit of detection (LOD) of the kit for Orf1ab target is 500 copies/mL, while that of the N501, Y501 and HV69-70del targets are 5000 copies/mL. The developed assay was applied to 165 clinical samples containing SARS-CoV-2 from 32 different lineages. The SARS-CoV-2 lineages were determined via the next-generation sequencing (NGS). The RT-qPCR results were in 100% agreement with the NGS results that 19 samples were N501Y and HV69-70del positive, 10 samples were N501Y positive and HV69-70del negative, 1 sample was N501Y negative and HV69-70del positive, and 135 samples were N501Y and HV69-70del negative. All the VOC-202012/01 positive samples were detected in people who have traveled from England to Turkey. The RT-qPCR test and the Sanger sequencing was further applied to 1000 SARS-CoV-2 positive clinical samples collected in Jan2021 from the 81 different provinces of Turkey. The RT-qPCR results were in 100% agreement with the Sanger sequencing results that 32 samples were N501Y positive and HV69-70del negative, 4 samples were N501Y negative and HV69-70del positive, 964 samples were N501Y and HV69-70del negative. The specificity of the 40 minutes RT-qPCR assay relative to the sequencing-based technologies is 100%. The developed assay is an advantageous tool for timely and representative estimation of the N501Y positive variants prevalence because it allows testing a much higher portion of the SARS-CoV-2 positives in much lower time compared to the sequencing-based technologies.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Design of a Novel Multiplex Real Time RT-PCR Assay for SARS-CoV-2 Detection
W. Zhen, G. J. Berry·bioRxiv·Jun 4, 2020
- Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a fourplex real-time quantitative reverse transcription-PCR assays.
Mathieu Durand, Philippe Thibault, … Simon Labbé·Microbial CellPeer-reviewed·Dec 28, 2021
- Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera
- Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction
Ivaine Taís Sauthier Sartor, Fernanda Hammes Varela, … COVIDa study group·Diagnostic Microbiology and Infectious DiseasePeer-reviewed·Jan 16, 2022
- Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
- Evaluation of the effects of SARS-CoV-2 genetic mutations on diagnostic RT-PCR assays
Takeru Nakabayashi, Yuki Kawasaki, … Satoshi Yuhara·bioRxiv·Jan 19, 2021